[{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harrow Health Announces Launch of IOPIDINE\u00ae 1% and MAXITROL\u00ae in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Marketing Authorisations for IOPIDINE\u00ae (apraclonidine) Fully Transferred to Essential Pharma as Change in UK NICE Guidelines for Glaucoma Treatment Expected to Lead to Increase in Patients\u2019 Need for Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"French Marketing Authorization for Iopidine\u00ae 1% (Apraclodinin) Transferred to Essential Pharma in Line with The Company's Medical Needs and Expansion Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Apraclonidine Hydrochloride
Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, a sympathomimetic used in glaucoma therapy. It is used as a short-term adjunctive therapy in open-angle glaucoma who are on maximally tolerated medical therapy requiring additional IOP reduction.
IOPIDINE (apraclonidine hydrochloride), is a short-term adjunctive therapy for chronic glaucoma to prevent or control intraocular pressure including after selective laser therapy, a form of laser eye surgery now recommended as the initial treatment for open angle glaucoma.
IOPIDINE 1% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha-adrenergic agonist, in a sterile isotonic solution for topical application to the eye.
FDA-approved IOPIDINE 1% is the gold standard for treating or preventing intraocular pressure during and after YAG laser eye surgery, which is required for about 40% of all prior cataract surgery patients.